Amalgamated Bank grew its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 57.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,921 shares of the medical research company’s stock after acquiring an additional 16,308 shares during the quarter. Amalgamated Bank’s holdings in Thermo Fisher Scientific were worth $7,837,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. BlackRock Inc. increased its holdings in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after acquiring an additional 22,165,530 shares in the last quarter. Veritas Asset Management LLP increased its holdings in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after acquiring an additional 1,286,259 shares in the last quarter. Harbour Capital Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after acquiring an additional 1,194,487 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock valued at $3,989,193,000 after acquiring an additional 695,079 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Thermo Fisher Scientific by 68.8% during the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock valued at $210,900,000 after acquiring an additional 559,400 shares in the last quarter. Hedge funds and other institutional investors own 83.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Amalgamated Bank Purchases 16,308 Shares of Thermo Fisher Scientific Inc (TMO)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/10/22/amalgamated-bank-purchases-16308-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 193.86 on Friday. The stock has a market cap of $75.63 billion, a PE ratio of 33.77 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $194.43. The firm has a 50-day moving average price of $190.66 and a 200 day moving average price of $176.57.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same quarter last year, the company earned $2.03 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on TMO shares. Leerink Swann boosted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective for the company in a report on Thursday, September 21st. Bank of America Corporation restated a “buy” rating and set a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Finally, BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $203.64.

In related news, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.